Year-end Sale % OFF 
Abstract
Metabolic disorders were evaluated in rats with alloxan diabetes mellitus after administration of 2-morpholino-5-phenyl-6H-1,3,4-thiadiazine (compound L-17). Administration of L-17 reduced the severity of metabolic disorders associated with diabetes mellitus. At the end of the experiment, the concentration of glucose, glycated hemoglobin, malonic dialdehyde, and catalase activity were significantly higher and peroxidase activity was significantly lower in the group of animals receiving L-17. The decrease of glycemia, glucose concentration, and glycated hemoglobin content was reached by the 3rd-4th week of the experiment. These data suggest that correction of biochemical parameters in rats with alloxan diabetes was reached after administration of L-17 for at least 3 weeks.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
